Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-06-20T02:27:31.962Z Has data issue: false hasContentIssue false

The role of creatine kinase in the diagnosis of Neuroleptic Malignant Syndrome

Published online by Cambridge University Press:  09 July 2009

Anne-Marie O'Dwyer*
Affiliation:
Department of Psychiatry, Waterford Regional Hospital, Ireland
Noel P. Sheppard
Affiliation:
Department of Psychiatry, Waterford Regional Hospital, Ireland
*
1Address for correspondence: Dr Anne-Marie O'Dwyer, Maudsley Hospital, Denmark Hill, London SE5 8AZ.

Synopsis

Elevation of serum creatine kinase (CK) concentrations occurs almost invariably in neuroleptic malignant syndrome (NMS). However, the role of CK levels in the diagnosis of the syndrome remains controversial. This study measured CK levels in patients who became pyrexial while on psychotropic medication and thereby mimicked some of the features of NMS. In all of these cases a diagnosis of infectious illness was made and patients responded to appropriate antibiotic therapy without alteration in psychotropic medication. Two other groups were studied for comparison – patients on psychotropics who were apyrexial and patients who became pyrexial but were not on psychotropics. Significant, unexpected elevations of CK were documented in 70% of those patients who became pyrexial while on psychotropics – in three cases elevation of concentrations to more than 1000 IU/1 (ten times reference value) were found. Thirty per cent of patients who became pyrexial but were not on psychotropics also developed elevation of CK but this was of a much smaller magnitude (lt; 200 IU/1 in five out of six cases). The results of the study suggest that elevation of CK is a non-specific finding, particularly in patients who become pyrexial on psychotropics. Use of CK as a diagnostic criterion may lead to overdiagnosis of NMS.

Type
Original Articles
Copyright
Copyright © Cambridge University Press 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addonozio, G., Susman, B. L. & Roth, S. D. (1986). Symptoms of Neuroleptic Malignant Syndrome in 82 consecutive in-patients. American Journal of Psychiatry 143, 15871590.Google Scholar
Adityanjee, M. D. (1991). The myth of elevated serum creatine phosphokinase level and Neuroleptic Malignant Syndrome. British Journal of Psychiatry 158, 706707.CrossRefGoogle ScholarPubMed
Goldwasser, H. D., Hooper, J. F. & Spears, N. M. (1989). Concomitant treatment of Neuroleptic Malignant Syndrome and psychosis. British Journal of Psychiatry 154, 102104.CrossRefGoogle ScholarPubMed
Harsch, H. H. (1987). Neuroleptic Malignant Syndrome: physiological and laboratory findings in a series of nine cases. Journal of Clinical Psychiatry 48, 328334.Google Scholar
Kellam, A. M. P. (1990). The (frequently) Neuroleptic (potentially) Malignant Syndrome. British Journal of Psychiatry 157, 169173.CrossRefGoogle Scholar
Levenson, J. L. (1985). Neuroleptic Malignant Syndrome. American Journal of Psychiatry 142, 11371145.Google ScholarPubMed
Rosebush, P. & Stewart, T. (1989). A prospective analysis of 24 episodes of Neuroleptic Malignant Syndrome. American Journal of Psychiatry 146, 717725.Google ScholarPubMed
Sullivan, C. F. (1987). A possible variant of the Neuroleptic Malignant Syndrome. British Journal of Psychiatry 151, 689690.CrossRefGoogle ScholarPubMed
Swartz, C. M. & Breen, K. J. (1990). Multiple muscle enzyme release with psychiatric illness. Journal of Nervous and Mental Diseases 178, 755759.CrossRefGoogle ScholarPubMed